Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.27 0.18 −2.42%
Market cap
$487.1M
P/E
57.3×
Fwd P/E
−2.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
63.92 0.00 0.00 0.00

+8 more quarters

P/S ratio
1.70 7.59 3.20 2.00
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(11.15) (9.80) (27.66) (10.55)
P/B ratio
0.96 1.75 1.94 1.11
EV/Sales
(0.09) 0.73 0.60 (0.52)
EV/EBITDA
1.56 0.00 0.00 1.53
EV/FCF
0.13 (0.25) (0.57) 0.49
Current Ratio
7.91 5.44 4.92 5.70
Net Debt/EBITDA
(3.40) 9.59 9.06 17.42
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
1.56% (31.32%) (10.79%) (9.51%)
Free Cash Flow Yield
(38.78%) (37.87%) (32.79%) (52.83%)
Free Cash Flow per Share
(0.75) (1.10) (0.43) (0.81)
Book value per Share
8.68 6.04 6.12 7.71
Free Cash Flow
(48.50) (70.50) (30.60) (59.20)
EV/EBIT
1.54 0.00 0.00 1.59
Other line items

Show all line items

Columns are period end dates